Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E. Gavriatopoulou M, et al. Among authors: gkotzamanidou m. Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Expert Opin Ther Targets. 2009. PMID: 19530987 Review.
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.
Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA. Kastritis E, et al. Among authors: gkotzamanidou m. Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6. Leukemia. 2013. PMID: 23183429
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Dimopoulos MA, et al. Among authors: gkotzamanidou m. Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26. Leukemia. 2010. PMID: 20739955
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA. Terpos E, et al. Among authors: gkotzamanidou m. Ann Oncol. 2012 Oct;23(10):2681-2686. doi: 10.1093/annonc/mds068. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492699 Free article.
High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E. Voskaridou E, et al. Among authors: gkotzamanidou m. Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11. Horm Metab Res. 2012. PMID: 22581647 Clinical Trial.
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA. Terpos E, et al. Among authors: gkotzamanidou m. Leukemia. 2014 Apr;28(4):928-34. doi: 10.1038/leu.2013.267. Epub 2013 Sep 18. Leukemia. 2014. PMID: 24045498
Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients.
Terpos E, Tasidou A, Eleftherakis-Papaiakovou E, Christoulas D, Gavriatopoulou M, Gkotzamanidou M, Roussou M, Kastritis E, Papadaki T, Dimopoulos MA. Terpos E, et al. Among authors: gkotzamanidou m. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):115-7. doi: 10.3816/CLML.2011.n.024. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21454208
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece. Terpos E, et al. Among authors: gkotzamanidou m. Int J Cancer. 2012 Feb 1;130(3):735-42. doi: 10.1002/ijc.26062. Epub 2011 May 30. Int J Cancer. 2012. PMID: 21484787
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy.
Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA. Migkou M, et al. Among authors: gkotzamanidou m. Eur J Haematol. 2011 Oct;87(4):323-9. doi: 10.1111/j.1600-0609.2011.01659.x. Epub 2011 Aug 26. Eur J Haematol. 2011. PMID: 21631590
37 results